Antigenic Imprinting

Antigenic imprinting—originally described as original antigenic sin (OAS) by Thomas Francis Jr. in 1960 and broadened into the concepts of antigenic seniority (Lessler et al., 2012) and immune imprinting (Gostic et al., 2016)—is the immunological phenomenon whereby an individual's primary life-course exposure to a specific pathogen strain (via childhood infection or initial vaccination) establishes a dominant pool of long-lived memory B cells and T cells that are preferentially recalled during subsequent encounters with antigenically drifted variants of the same pathogen. In vertebrate immunology, antigenic imprinting operates as a competitive evolutionary trade-off: when the recalled epitopes remain conserved and neutralizing across variants, imprinting accelerates cross-protective recall immunity; conversely, when antigenic drift mutates the neutralizing receptor-binding surface while leaving non-neutralizing or subdominant epitopes intact, competitive suppression of de novo naive B-cell recruitment by pre-existing memory clones can narrow neutralizing breadth, drive antibody-dependent enhancement in flaviviruses, and create birth-cohort susceptibility patterns against influenza A and SARS-CoV-2 variants.

When a naive host encounters a viral glycoprotein—such as influenza hemagglutinin (HA), SARS-CoV-2 Spike (S), or dengue Envelope (E)—for the first time, naive B lymphocytes recognizing immunodominant surface epitopes (see immunodominance) enter secondary lymphoid germinal centers. Guided by follicular helper T cells (T_FH), these B cells undergo Activation-Induced Cytidine Deaminase (AID)-mediated somatic hypermutation and affinity maturation, differentiating into long-lived bone-marrow plasma cells and circulating IgG⁺ memory B cells (B_MEM).

Years later, when the host is infected or boosted with an antigenically drifted variant that shares conserved framework epitopes (E_conserved) with the founding strain but carries novel mutated epitopes (E_novel) on its receptor-binding site, pre-existing B_MEM clones targeting E_conserved enjoy four kinetic and thermodynamic advantages over naive B cells (B_naive) specific for E_novel:

1. Precursor Frequency and Activation Threshold Advantage: Antigen-experienced B_MEM cells circulate at 10- to 1,000-fold higher precursor frequencies than variant-specific B_naive cells, express class-switched IgG B-cell receptors (BCRs) whose cytoplasmic tails enhance Syk/PI3K signaling, and express elevated costimulatory molecules (CD80, CD86, and CD27), enabling rapid extrafollicular plasmablast differentiation within 3 to 5 days.
2. Epitope Masking and Antigen Clearance by Secreted IgG: High-titer circulating antibodies and early plasmablast IgG produced by recalled B_MEM clones bind conserved regions of the variant viral glycoprotein, sterically masking adjacent E_novel epitopes or accelerating Fcγ-receptor-mediated immune-complex clearance by macrophages before high-threshold B_naive cells can engage sufficient antigen.
3. Inhibitory FcγRIIB Feedback on Naive B Cells: Antigen–IgG immune complexes cross-link the activating BCR alongside the low-affinity inhibitory receptor FcγRIIB (CD32B) on naive B cells, recruiting the inositol phosphatase SHIP-1 to hydrolyze PIP₃ and suppress naive B-cell activation.
4. Competition for T_FH Help in Secondary Germinal Centers: As shown by Gabriel D. Victora and colleagues (Mesin et al., 2020; Schiepers et al., 2023) using fate-mapping AID-CreERT2 mice and molecular fate-tracking of serum antibodies, high-affinity imprinted B_MEM clones capture and endocytose antigen more efficiently than low-affinity germline B_naive cells, displaying denser peptide–MHC Class II complexes to monopolize limited CD40L and IL-21 signals from T_FH cells.

In the 1950s, Fred M. Davenport, Albert V. Hennessy, and Thomas Francis Jr. measured hemagglutination-inhibition (HI) antibody titers across age cohorts following infection or vaccination with newly drifted influenza A (H1N1) strains. They discovered that children, young adults, and older adults infected with the same contemporary influenza strain mounted antibody responses that peaked against whichever historical strain had circulated during each birth cohort's childhood: cohorts born before 1918 peaked against 1918 H1N1-like antigens, cohorts born in the 1930s peaked against PR8/1934 H1N1, and cohorts born after 1947 peaked against FM1/1947 H1N1. In 2012, Justin Lessler and colleagues quantified this hierarchy across H3N2 circulation and termed it antigenic seniority: each subsequent exposure triggers a back-boost of antibodies recognizing previously encountered strains, anchoring lifelong geometric mean titers to strains encountered around age 6.

In 2016, Katelyn Gostic, Michael Worobey, and James Lloyd-Smith demonstrated that childhood imprinting to the two phylogenetic clades of influenza A hemagglutinin—HA Group 1 (seasonal H1, H2, and avian H5N1) vs. HA Group 2 (seasonal H3 and avian H7N9)—explains the opposing age distributions of human avian influenza fatalities:

• Cohorts born before 1968 (imprinted in childhood with Group 1 H1N1 or H2N2) possessed conserved Group 1 HA-stalk memory that conferred ~75% protection against fatal H5N1 (Group 1), but left them susceptible to H7N9 (Group 2).
• Cohorts born between 1968 and 1977 (imprinted in childhood with Group 2 H3N2 after the 1968 pandemic) were protected against Group 2 H7N9, but suffered high mortality from Group 1 H5N1.

In dengue virus (DENV 1–4) infections, secondary heterotypic infection recalls cross-reactive B_MEM clones primed against the primary serotype; because these antibodies bind the heterologous serotype with sub-neutralizing avidity, they opsonize virions for uptake into FcγRIIA⁺ monocytes (antibody-dependent enhancement), elevating viremia and vascular permeability.

During the SARS-CoV-2 pandemic, primary immunization with ancestral Wuhan-Hu-1 Spike imprinted global B-cell repertoires. When Omicron variants (BA.5, XBB.1.5, JN.1) emerged with >30 Spike receptor-binding domain substitutions, single-cell BCR tracking (Schiepers et al., 2023) showed that bivalent boosters (containing ancestral Wuhan-Hu-1 + Omicron BA.5) preferentially recalled ancestral-imprinted memory B cells, whereas switching to monovalent variant-only boosters (omitting ancestral antigen) or administering repeated variant exposures recruited de novo variant-specific naive B cells and drove secondary affinity maturation of cross-reactive clones. Modern vaccinology overcomes unfavorable imprinting through monovalent variant exclusivity, chimeric hemagglutinin (cHA) stalk immunogens, glycan masking of variable decoy loops, and prolonged germinal-center adjuvants.

Why did monovalent XBB.1.5 COVID-19 boosters elicit broader variant neutralization than bivalent Wuhan + BA.5 boosters?

In a bivalent (50% ancestral Wuhan + 50% variant) vaccine, the presence of the ancestral priming antigen allows high-affinity Wuhan-imprinted memory B cells to outcompete naive B cells for antigen and T_FH help in the lymph node. Omitting the ancestral antigen in the monovalent XBB.1.5 formulation engaged B cells capable of binding the mutated XBB.1.5 RBD, driving affinity maturation toward the new variant.

How does antigenic seniority differ from original antigenic sin?

Whereas classical original antigenic sin viewed the primary childhood infection as creating a rigid distortion of all future antibody responses, antigenic seniority (Lessler et al., 2012) demonstrates that every subsequent infection or vaccination across life quantitatively back-boosts antibodies to previously encountered strains, creating a smooth age-stratified titer gradient peaking at strains circulating during the first decade of life.

1. Francis, T., Jr. (1960). "On the doctrine of original antigenic sin." Proceedings of the American Philosophical Society, 104(6), 572–578. https://www.jstor.org/stable/985534
2. Lessler, J., Riley, S., Read, J. M., Wang, S., Zhu, H., Smith, G. J. D., Guan, Y., Jiang, C. Q., & Cummings, D. A. T. (2012). "Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China." PLOS Pathogens, 8(7), e1002802. https://doi.org/10.1371/journal.ppat.1002802
3. Gostic, K. M., Ambrose, M., Worobey, M., & Lloyd-Smith, J. O. (2016). "Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting." Science, 354(6313), 722–726. https://doi.org/10.1126/science.aag1322
4. Schiepers, A., van 't Wout, M. F. L., Greaney, A. J., Zost, S. J., Muramatsu, H., Lin, P. J. C., Tam, Y. K., Mesin, L., Starr, T. N., Pardi, N., Bloom, J. D., & Victora, G. D. (2023). "Molecular fate-mapping of serum antibodies reveals the effects of antigenic imprinting on repeated immunization." Nature, 615(7952), 482–489. https://doi.org/10.1038/s41586-023-05715-3